Sato Atushi, Shimada Ken, Taguchi Susumu
Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki-ku, Yokohama, Kanagawa 224-8503, Japan.
Gan To Kagaku Ryoho. 2003 Sep;30(9):1260-9.
Until recently, few chemotherapy options were available to treat metastatic colorectalcancer. For years, the standard chemotherapy has been a Fluorouracil (5-FU) alone of 5-FU with leucovorin (LV) modulation. The newer cytotoxic drugs irinotecan (CPT-11) and oxaliplatin (L-OHP) has generated further improvement in survival. Additionally, improvement in convenience of drug administration has been achieved with the development of oral fluoropynmidines. In randomized trials, oral fluoropyrimidines were equally effective to bolus 5-FU and LV. Recently completed or ongoing clinical trials to study novel targeting agents have initiated a new generation of drug development such as angiogenesis inhibitors and epidermal growth factor inhibitors. Randomized trials will determine the impact of these newer agents on survival and quality of life.
直到最近，治疗转移性结直肠癌的化疗方案还很少。多年来，标准的化疗一直是单独使用氟尿嘧啶（5-FU）或使用亚叶酸（LV）调节的5-FU。新型细胞毒性药物伊立替康（CPT-11）和奥沙利铂（L-OHP）进一步提高了生存率。此外，口服氟嘧啶的研发提高了给药的便利性。在随机试验中，口服氟嘧啶与推注5-FU和LV同样有效。最近完成或正在进行的研究新型靶向药物的临床试验开启了新一代药物的研发，如血管生成抑制剂和表皮生长因子抑制剂。随机试验将确定这些新型药物对生存率和生活质量的影响。
